A case-driven hypothesis built around a single 53-year-old male with T2DM proposes that semaglutide-induced sarcopenia creates a self-reinforcing metabolic trap. After titrating semaglutide from 0.25 to 1 mg weekly, the patient lost 14 kg over roughly one year but developed muscle weakness, reduced mobility, and refractory hyperglycemia (fasting glucose 300 mg/dL, HbA1c 9%) that persisted even after drug discontinuation. The authors hypothesize a GLP-1R–mTOR–satellite cell axis disruption suppressing anabolic mTORC1/IGF-1 signaling by an estimated 25–35%, amplifying FOXO/ubiquitin-proteasome catabolism, elevating myostatin and GDF15, and ultimately reducing GLUT4-mediated muscle glucose uptake by 35–45% — converting skeletal muscle from glucose sink to metabolic liability.
This hypothesis arrives at a genuinely important inflection point. GLP-1 receptor agonists are near-ubiquitous in metabolic medicine, yet their effects on skeletal muscle quality — as opposed to fat mass — remain poorly characterized in long-term trials. The concern is mechanistically plausible: mTORC1 suppression via AMPK is a known downstream consequence of caloric restriction mimicry, and muscle loss during GLP-1RA therapy has been documented in small cohorts. However, the evidence base here is critically weak. A single case report cannot establish causation, and the proposed numeric estimates (25–35% mTORC1 suppression, 15–25% hyperglucagonemia rise) are speculative extrapolations, not measured values. The hypothesis is intellectually stimulating and identifies a legitimate research gap, but it should be read strictly as hypothesis-generation — incremental at best until prospective, muscle-biopsy-validated trials are conducted.